Danaher Corporation (DHR) has been benefiting from strength in its Life Sciences segment, driven by stable demand in the academic and applied markets, and strong momentum in the genomics consumables business. The company has been witnessing positive responses from its new products like IDBS' Polar Insight and Molecular Devices' CellXpress.ai, which help accelerate the drug discovery process and bring new therapies to market faster. Also, in the Diagnostics unit, new solutions like Beckman Coulter's DxI 9000 ...